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Purpose: Great progress has been made in the adjuvant treatment of colon cancer. The aim of this study was to evaluate 
the efficacy of postoperative adjuvant chemotherapy using the FOLFOX regimen in patients with stage III and high-risk 
stage II colon cancer.
Methods: Eighty-two patients who underwent a potentially curative resection for stage III or high-risk stage II colon can-
cer were enrolled in this retrospective study. They received FOLFOX4 or modified FOLFOX6. The primary endpoint was 
disease-free survival.
Results: During the median follow-up of 37 months (range, 21 to 61 months), 14 patients experienced disease relapse. The 
disease-free survival rate at 3 years was 82.9%: 84.6% for stage II and 82.6% for stage III. At the time of the analysis, 8 pa-
tients were dead from recurrence. The probability of overall survival at 5 years was 74.5%: 90% for stage II and 74.6% for 
stage III. Grade 3 or 4 hematologic adverse events included neutropenia (40.2%), anemia (2.4%), and thrombocytopenia 
(1.2%). Gastrointestinal toxicities included grade 3 or 4 nausea (4.9%) and stomatitis (2.4%). Peripheral sensory neuropa-
thy was observed in 81.7% of the patients during treatment. Of the 11 patients (13.4%) who had grade 3 peripheral sensory 
neuropathy during treatment, grade 3 symptoms were persistent in 3 patients with gait disturbance at the time of analysis. 
No treatment-related deaths were recorded.
Conclusion: Postoperative chemotherapy using the FOLFOX regimen, oxaliplatin in combination with 5-fluorouracil and 
leucovorin, is effective and tolerable in patients with stage III and high-risk stage II colon cancer.
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Intergroup trial (INT-0035) for adjuvant 5-fluorouracil (5-FU) plus 
levamisole therapy in patients with stage III colon cancer [3], 5-FU 
plus leucovorin (LV) combination (FL) therapy became the stan-
dard chemotherapy for stage III colon cancer [4, 5]. Beginning with 
new millennium, oxaliplatin, a third-generation platinum deriva-
tive alkylating agent that inhibits DNA replication, emerged as one 
of the most effective chemotherapeutics (in terms of response rate 
and progression-free survival) for metastatic colorectal cancer when 
combined with 5-FU and LV [6, 7]. To determine if oxaliplatin in 
combination with 5-FU and LV can also show improved efficacy 
in adjuvant settings, Andre et al. [8] conducted an international 
phase III clinical trial, the MOSAIC (the Multicenter International 
Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant 
Treatment of Colon Cancer) study and demonstrated that adding 
oxaliplatin to a regimen of bolus and continuous-infusion 5-FU 
combined with LV (FOLFOX4) improved disease-free survival 
(DFS) significantly in stage II and III colon cancer compared with 
the same regimen of 5-FU and LV (LV5FU2). Based on the results 
of the MOSAIC study, the US Food and Drug Administration ap-
INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy 
in Korea and accounted for approximately 22,000 new cancer cases 
and 6,800 deaths in 2008 [1]. As many as 40% to 50% of patients 
who undergo a potentially curative surgery alone will ultimately 
relapse and die of metastatic disease [2].
Over the past years, considerable progress has been made in the 
adjuvant treatment of patients with colon cancer. Following the 
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proved the FOLFOX4 regimen for postoperative adjuvant therapy 
in patients with stage III colon cancer in November 2004. Addi-
tional follow-up of the MOSAIC trial also proved the persistent 
DFS benefit of the FOLFOX4 regimen in the adjuvant treatment 
of colon cancer and confirmed that this effect translated into an 
overall survival (OS) benefit [9]. The aim of this retrospective study 
was to evaluate the efficacy and the toxicity of the FOLFOX regi-
men as postoperative adjuvant chemotherapy in patients with stage 
III and high-risk stage II colon cancer on whom a potentially cu-
rative surgical resection had been performed.
 
METHODS
Patients were eligible when they had undergone a potentially cura-
tive surgical resection of pathologically proven stage III (any TN1/ 
2M0) or high-risk stage II colon cancer. Stage II disease was clas-
sified as high risk when it had at least one of the following factors: 
T4a/4b, tumor perforation, bowel obstruction, a poorly-differen-
tiated tumor, and venous or lymphatic invasion. As in the MOSAIC 
trial [8], colon cancer was defined by the presence of the inferior 
margin of the tumor above the peritoneal reflection. Other eligi-
bility criteria included age between 18 and 79 years, Eastern Co-
operate Oncology Group performance scale of two or less, the ab-
sence of prior chemotherapy, immunotherapy or radiotherapy, 
and adequate blood counts and liver and kidney functions. Before 
treatment, written informed consent, based on information about 
chemotherapeutic drugs, treatment schedule and toxicity, was pro-
vided by all patients. For safe delivery of the chemotherapeutic 
drugs, a central venous port was implanted into the subclavian 
vein in all patients. Treatment was started not later than eight weeks 
after surgery.
Treatment
Patients received the FOLFOX4 or the modified FOLFOX6 (mFO- 
LFOX6) regimen. Both original oxaliplatin (Eloxatin
®, Sanofi-
Aventis, Paris, France) and generic oxaliplatin (OXP
®, Shinpoong 
Pharmaceutical Co., Seoul, Korea) were administered randomly. 
The FOLFOX4 regimen consisted of LV, 200 mg/m
2/day given as 
a 2-hour infusion, followed by a bolus 5-FU, 400 mg/m
2, and a 22-
hour continuous infusion of 5-FU, 600 mg/m
2, repeated for 2 con-
secutive days. Oxaliplatin, 85 mg/m
2, was administered on day 1 
only and was given as a 2-hour infusion in 250 mL of dextrose 5%, 
concurrent with LV. The mFOLFOX6 regimen included oxalipla-
tin, 85 mg/m
2 in 250 mL of dextrose 5%, concurrent with LV, 400 
mg/m
2, given as a 2-hour intravenous infusion on day 1, followed 
by a bolus 5-FU, 400 mg/m
2, on day 1 and a continuous 5-FU, 1,200 
mg/m
2/day, on day 1 and 2 (46-hour continuous infusion of a to-
tal 5-FU of 2,400 mg/m
2). Oxaliplatin and LV were given separately 
via a Y-connector. In each cycle, routine antiemetic prophylaxis 
was performed with a 5-hydroxytryptamine 3 receptor antagonist 
(granisetron hydrochloride). The cycles were repeated every 2 
weeks.
Before starting each cycle, patients were assessed by using the Na-
tional Cancer Institute common toxicity criteria. Dose modifica-
tions were performed according to predefined guidelines based on 
toxicities, as described in the MOSAIC trial [8]. Dose reductions 
were based on the worst adverse effects observed during the pre-
vious cycle. The dose of oxaliplatin was reduced by 20% in cases 
of persistent (at least 14 days) paresthesia, temporary painful par-
esthesia or functional impairment. Together with reductions in 
the dose of oxaliplatin, both the bolus and the infusion dose of 5- 
FU were reduced by 20% in the event of grade 3/4 neutropenia or 
thrombocytopenia (or both), diarrhea, stomatitis, or other drug-
related adverse effects of grade 3. Chemotherapy was delayed un-
til recovery if neutrophils decreased to less than 1.5 × 10
9/L or plate-
lets decreased to less than 100 × 10
9/L or for significant persisting 
nonhematologic toxicity. In cases of persistent painful paresthesia 
or functional impairment even after dose reduction of the oxalipl-
atin, the regimen was switched to the Mayo Clinic regimen or 
capecitabine monotherapy.
Follow-up
Patients were assessed before adjuvant treatment, every two weeks 
during treatment, and then every three months for three years. Dur-
ing treatment, medical history, physical examination, neurologic 
assessment, CBC, and liver and kidney function tests were assessed 
at baseline and were repeated every cycle, and the serum carcino-
embryonic antigen (CEA) level and abdominopelvic, and low-dose 
chest computed tomography (CT) were assessed every six cycles. 
After completion of the chemotherapy, specific oncologic assess-
ment included serum CEA level and chest radiography every three 
months, and abdominopelvic and low-dose chest CT biannually. 
Patients had colonoscopy postoperatively at one year, and thereafter 
as indicated. Patients were monitored for adverse effects through-
out the treatment period and until 28 days after the last cycle of 
chemotherapy unless treatment-related adverse effects required 
additional follow-up. The diagnosis of recurrence was made on 
the basis of imaging studies and, if indicated, biopsy.
Statistical analysis
Data were entered into a spreadsheet program and subsequently 
imported into a statistic programs (Prism
TM, version 4; GraphPad 
Software, San Diego, CA, USA). The primary end-point was DFS, 
defined as the time from treatment to relapse of colon cancer or 
death as a result of any cause. Secondary efficacy variables were 
safety, including long-term adverse effects, and overall survival. 
Safety analyses included patients who had received at least one cy-
cle of treatment. Survivals were calculated using the Kaplan-Meier 
method and were analyzed using the log-rank test.
RESULTS
Study population
Eighty-two patients were enrolled in this retrospective study from Journal of The Korean Society of
Coloproctology
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April 2006 to December 2008. The baseline characteristics of the 
enrolled patients are shown in Table 1. The median age was 59 years 
(range, 28 to 79 years), and the most common site of the primary 
tumor was the sigmoid colon (42 patients), followed by the right-
sided colon (16 patients) and the rectosigmoid junction (12 pa-
tients). A laparoscopic colectomy was performed in 49 patients 
(conversion was necessary in 3 patients) and an open colectomy 
in 33.
Postoperative pathologic characteristics are detailed in Table 2. 
Sixty-nine patients were confirmed to have stage III disease and 13 
to have high-risk stage II disease. High-risk factors in stage II in-
cluded lymphatic/vascular invasion in eight patients, T4b tumors 
in four patients, and obstruction and perforation in two patients.
The details of FOLFOX chemotherapy are presented in Table 3. 
As to the regimen, the FOLFOX4 regimen was administered in 
56 patients and the mFOLFOX6 regimen in 26. Patients received 
at least one cycle of the FOLFOX regimen, and 67 patients (82%) 
were able to receive at least 10 of 12 cycles of the FOLFOX regi-
men, with a median of 12 cycles (range, 1 to 12 cycles). For oxali-
platin preparation, Eloxatin
® was administered in half of the pa-
tients and OXP
® in the remaining half.
Toxicity
As shown in Table 4, the most frequent adverse events during the 
treatment were peripheral sensory neuropathy (PSN; 81.7%), neu-
tropenia (74.4%), diarrhea (65.9%), and nausea (62.2%). There were 
no differences in toxicity profiles between patients who received 
the FOLFOX4 regimen and those who received the mFOLFOX6 
regimen. Grade 3/4 hematologic adverse events included neutro-
penia (40.2%), anemia (2.4%), and thrombocytopenia (1.2%). Gas-
trointestinal toxicities included grade 3/4 nausea (4.9%), stomati-
tis (2.4%). Of the 11 patients (13.4%) who had grade 3 PSN dur-
ing treatment, grade 3 symptoms were still present in 3 patients 
with gait disturbance at the time of analysis. No treatment-related 
deaths were recorded.
Embarrassingly, a catheter embolization to the pulmonary artery 
developed in a 37-year-old male patient with stage IIC disease. Ret-
rospective radiologic review of plain chest radiographs confirmed 
evidence of compression of the catheter at the costo-clavicular junc-
tion (pinch-off syndrome) (Fig. 1A). He did not complain of any 
clinical manifestations associated with it, and the embolized frag-
ment was found incidentally by routine chest radiography several 
Table 1. Baseline characteristics of patients
Variable    No. (%)
Median age (range, yr)    59 (28-79)
Age (yr)
   <65  54 (65.9)
   ≥65  28 (34.1)
Sex
   Male  48 (58.5)
   Female  34 (41.5)
Anatomic tumor location
   Right colon  16 (19.5)
   Transverse colon  3 (3.7)
   Left colon 9 (11)
   Sigmoid colon  42 (51.2)
   Rectosigmoid junction  12 (14.6)
Preoperative serum CEA (ng/mL)
   <5  68 (82.9)
   ≥5  14 (17.1)
Method of surgery
   Laparoscopic colectomy
a  49 (59.8)
   Open colectomy  33 (40.2)
CEA, carcinoembryonic antigen.
aThree cases of conversion were included.
Table 2. Pathologic characteristics of patients
Variable No.
Histologic differentiation
   Well differentiated 27
   Moderately differentiated 45
   Poorly differentiated   3
   Mucinous/signet ring cell 6/1
Depth of invasion
   T1   4
   T2   4
   T3 61
   T4 (T4a/T4b) 13 (8/5)
No. of nodes involved
   0 13
   1-4 (N1a/N1b) 46 (28/18)
   ≥5 (N2a/N2b) 23 (13/10)
Lymphatic invasion (-/+) 48/34
Vascular invasion (-/+) 65/17
Perineural invasion (-/+) 65/17
p53 mutation (-/+) 28/54
Disease stage
   Stage II (IIA/IIC) 13 (9/4)
   Stage III (IIIA/IIIB/IIIC) 69 (6/50/13)
High risk factor in stage II
   Obstruction   2
   Perforation   2
   Lymphatic/vascular invasion   8
   T4b   4Journal of The Korean Society of
Coloproctology
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months after the completion of 12 cycles of the FOLFOX4 regi-
men (Fig. 1B). The embolized catheter was successfully retrieved 
by using an interventional radiologic approach (Fig. 2).
Outcome
Fourteen patients experienced disease relapse during the median 
follow-up of 37 months (range, 21 to 61 months). The diverse pat-
terns of relapse are shown in Table 5. The Kaplan-Meier curve for 
82 patients is shown in Fig. 3A. DFS rates at 2 and 3 years were 
84.1% and 82.9%, respectively. No significant difference in DFS 
was observed between patients who received the FOLFOX4 regi-
men and those who received the mFOLFOX6 regimen. The 3-year 
DFS rates were 83.9% for the FOLFOX4 regimen and 80.8% for 
the mFOLFOX6 regimen (P = 0.755). The Kaplan-Meier estimates 
of the DFS rates at 3 years according to stage are shown in Fig. 3B: 
84.6% for stage II and 82.6% for stage III (hazard ratio [HR], 0.873; 
P = 0.86). At the time of analysis, eight patients had died due to 
recurrence, but no patients had died without recurrence. The prob-
abilities of OS at 3 and 5 years were 87.5% and 74.5%, respectively. 
According to stage, estimates of OS at 5 years were 90% for stage 
II and 74.6% for stage III.
DISCUSSION
Adjuvant chemotherapy given after a potentially curative surgery 
was developed to reduce the risk of disease relapse, either as local 
recurrences or distant metastases, in patients with stage II and III 
colon cancer. A traditional endpoint of adjuvant clinical trials for 
colon cancer has been 5-year OS. Recent adjuvant trials, however, 
use 3-year DFS as the primary endpoint on the grounds that re-
lapse of disease occurs within the first 3 years in the majority of 
patients, with the relapse rate reaching a peak in the second year 
[10], and that a recent analysis of pooled data by Sargent et al. [11] 
from over 20,000 patients with stage III colon cancer found that 
3-year DFS highly correlated with 5-year OS, suggesting that 3-year 
DFS is an appropriate primary endpoint for adjuvant colon cancer 
clinical trials of fluoropyrimidine-based regimens. Most recently, 
Table 3. Details of the FOLFOX chemotherapy
Variable    No. (%)
FOLFOX regimen
   FOLFOX4    56 (68.3)
   Modified FOLFOX6    26 (31.7)
Median cycles of chemotherapy (range)    12 (1-12)
Product of oxaliplatin
   Original (Eloxatin
®) 41 (50)
   Generic (OXP
®) 41 (50)
Table 4. Adverse events
Adverse events All grades Grades 3 and 4
Hematologic
   Neutropenia 61 (74.4) 33 (40.2)
   Anemia 38 (46.3) 2 (2.4)
   Thrombocytopenia 24 (29.3) 1 (1.2)
Gastrointestinal
   Diarrhea 54 (65.9) 1 (1.2)
   Nausea 51 (62.2) 4 (4.9)
   Vomiting 12 (14.6) 1 (1.2)
   Stomatitis 30 (36.6) 2 (2.4)
Sensory neuropathy 67 (81.7) 11 (13.4)
Alopecia 4 (4.9) NA
Values are presented as number (%).
NA, not applicable. 
A B
Fig. 1. Catheter fracture due 
to pinch-off syndrome. (A) 
The catheter was entrapped 
at the point where the cathe-
ter crosses between the clav-
icle and the first rib (arrow). 
(B) Distal portion of the cath-
eter was fractured and embo-
lized to the right pulmonary 
artery (arrows).Journal of The Korean Society of
Coloproctology
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Sargent et al. [12], from six trials of 12,676 patients, validated that 
results based on DFS assessed after 2 or 3-year median follow-up 
are appropriate primary endpoints for adjuvant stage III colon 
cancer trials with 5-FU with or without oxaliplatin or irinotecan.
The MOSAIC trial demonstrated the superiority of oxaliplatin in 
FOLFOX4, compared to LV5FU2, in improving DFS in patients 
with resected stage II and III colon cancer [8]. The DFS at 3 years 
was 78.2% for the FOLFOX regimen versus 72.9% for the LV5FU2 
regimen. The FOLFOX4 regimen increased the probability that a 
patient would be alive and disease-free at 3 years by 5.3%. The HR 
for recurrence in the group given the FOLFOX regimen, as com-
pared with the LV5FU2 group, was 0.77 (95% confidence interval 
[CI], 0.65 to 0.91; P = 0.002); treatment with the FOLFOX regi-
men resulted in a 23% reduction in the relative hazard of a DFS 
event. The probability of OS at 3 years was 87.7% for the FOLFOX 
regimen and 86.6% for the LV5FU2 regimen.
The National Surgical Adjuvant Breast and Bowel Project 07 
(NSABP-07) trial comparing the oxaliplatin and bolus 5-FU/LV 
A B C D
Fig. 2. Port catheter retrieval by using an interventional radiologic approach. (A) A direct radiograph shows the dislodged port catheter within 
the right pulmonary artery. (B-D) By catching the displaced tip with a gooseneck snare, we retrieved the catheter through the right femoral vein.
Table 5. Patterns of relapse
Lung metastases 3
Systemic lymph nodes metastases 3
Liver metastases 2
Liver metastases + peritoneal seeding 1
Multiple bone metastases + peritoneal seeding 1
Multiple bone metastases 1
Peritoneal seeding 1
Krukenberg tumor 1
Regional recurrence 1
Fig. 3. Kaplan-Meier curve for disease-free survival (A) in all patients and (B) by stage.
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(FLOX) regimen to the bolus 5-FU/LV (FULV, Roswell Park regi-
men) regimen for resected stage II and III colon cancer also dem-
onstrated the superiority of an oxaliplatin-based regimen in the 
adjuvant treatment of colon cancer [13]. Three-year DFS was 76.1% 
in the FLOX group compared to 71.8% in the FULV arm; com-
pared to the FULV regimen, the FLOX regimen increased the prob-
ability that a patient would be alive and disease free at 3 years by 
4.3%. The relative hazard of the DFS event was reduced by 20% 
with FLOX treatment as compared to FULV treatment, with a HR 
of 0.80 (95% CI, 0.69 to 0.93; P = 0.0034). These data confirm that 
a significant DFS benefit can be attained when oxaliplatin is added 
to fluoropyrimidine-based regimens.
The DFS and the OS rates at 3 years in the present retrospective 
study were 82.9% and 87.5%, respectively, and these results are fa-
vorably compared with those of the MOSAIC and the NSABP-07 
trials. The updated results of the MOSAIC trial showed a trend to-
ward improvement in survival for patients treated with the FOLFOX 
regimen [9]. The DFS rates at 5 years were 73.3% for the FOLFOX 
regimen and 67.4% for the LV5FU2 regimen (HR, 0.80; 95% CI, 
0.68 to 0.93; P = 0.003). The OS rates at 6 years were 78.5% for the 
FOLFOX regimen and 76.0% for the LV5FU2 regimen (HR, 0.84; 
95% CI, 0.71 to 1.00; P = 0.046). Similar results were obtained in 
the current study and the probability of OS at 5 years was 74.5%.
In the MOSAIC trial, the significant DFS and OS benefits in the 
overall FOLFOX group were driven entirely by the favorable effect 
in the subgroup of patients with stage III disease. The clinical ben-
efit of the FOLFOX4 regimen, compared with the LV5FU2 regi-
men, in terms of 6-year OS and 5-year DFS reached statistical sig-
nificance and clinical relevance only among stage III patients. For 
stage II patients, there were no statistically significant improved 
5-year DFS and 6-year OS. The role of postoperative adjuvant ther-
apy for stage II colon cancer still remains controversial, and the 
MOSAIC trial showed only a trend toward improved DFS at 5 
years in patients with high-risk stage II disease treated with the 
FOLFOX4 regimen, as compared to patients treated with the LV5- 
  FU2 regimen. As suggested by Andre et al. [9], future studies to 
identify high-risk stage II disease patients to evaluate oxaliplatin-
based adjuvant chemotherapy in this subgroup of patients are nec-
essary.
Diverse spectra of toxicities were observed in chemotherapy with 
oxaliplatin in combination with 5-FU and LV. The toxicity profile 
of the FOLFOX4 regimen seen in the MOSAIC trial is somewhat 
distinct from that seen with the FLOX regimen in the NSABP-07 
trial. One of the most specific safety concerns associated with ox-
aliplatin-based chemotherapy is PSN. PSN was observed in 92% 
of the patients who received the FOLFOX regimen and over 12% 
was grade 3, compared with 15.6% with 0.2% grade 3 for the LV5- 
FU2 arm [8]. Fortunately, this toxicity showed improvement with 
time. At one year, 11 patients (1.1%) continued to have grade 3 pe-
ripheral neurosensory symptoms, and this declined to 7 patients 
(0.7%) at 18 months [9]. In the NSABP-07 trial, grade 3 PSN was 
seen in 8.2% of patients and grade 4 in 0.2% of patients receiving 
the FLOX regimen, compared with 0.7% with grade 3 PSN only 
in the FULV regimen [13]. At 1 year from random assignment, 
the rate of grade 3 PSN in the FLOX arm was 0.6%. The lower in-
cidence of PSN seen in the NSABP C-07 trial was a likely result of 
the lower cumulative dose of oxaliplatin given in the NSABP C-07 
trial (nine planned doses of 85 mg/m
2) than in the MOSAIC trial 
(12 planned doses of 85 mg/m
2) [13]. Conversely, more grade 3/4 
diarrhea was observed with the FLOX regimen in the NSABP C-07 
trial (38%) than was observed with the FOLFOX regimen in the 
MOSAIC trial (10.8%) and might be the result of different treat-
ment schedules. Furthermore, the FLOX regimen was associated 
with an increased risk of bowel wall injury (BWI) syndrome, which 
has not been reported for the FOLFOX4 regimen, and five among 
15 deaths in the FLOX arm were attributed to chemotherapy-in-
duced enteropathy [13].
Although PSN developed in 81.7% of patients during treatment 
in the current study, 83.5% of them were of grade 1/2. However, 3 
of the 11 patients with grade 3 PSN were still complaining of gait 
disturbance associated with PSN at the analysis. In the MOSAIC 
trial, grade 3/4 neutropenia was observed in 41% of the patients in 
the FOLFOX arm compared with less than 5% of the patients in 
the LV5FU2 arm; neutropenic infection or fever was, however, rare 
in both groups (1.8% and 0.2%, respectively) [8]. In the NSABP-07 
trial, infection associated with grade 3/4 neutropenia was seen in 
1.0% of patients receiving the FULV regimen and in 2.2% of pa-
tients receiving the FLOX regimen [13]. Similarly, grade 3/4 neu-
tropenia was seen in 40.2% in the present study, but no neutrope-
nic infection or fever developed. The all-cause mortality during 
treatment with each of the oxaliplatin-containing regimens was 
low and was the same as in the control arms (0.5% for the FOLFOX4 
regimen in the MOSAIC trial and 1.2% for the FLOX regimen in 
the NSABP C-07 trial) [8, 13]. No treatment-related deaths were 
recorded in this study.
In addition to toxicities associated with chemotherapeutic agents, 
complications associated with central venous port systems need 
to be taken into consideration. We experienced a case of catheter 
fracture and embolization of the distal fragment to the right pul-
monary artery. Catheter fracture can be caused by entrapment of 
the catheter between the first rib and the clavicle (pinch-off syn-
drome). Biffi et al. [14] reported this complication in 9 out of 1,320 
subclavian port placements (0.68%). Usually, patients have no symp-
toms from the embolized catheter fragment itself, but when cath-
eter embolization develops during treatment, it may have disas-
trous results; leakage of chemotherapeutic drugs out into the sur-
rounding tissue can cause extensive necrosis [15]. In our patient, 
fortunately, catheter embolization developed several months after 
the completion of scheduled chemotherapy, and the embolized 
catheter was successfully retrieved by using an interventional ra-
diologic approach. The radiologic retrieval of embolized fragments 
is the preferred method of treatment, and it has a high success rate 
[14]. Here, we can take a lesson in the care of the central venous 
port system; it should be removed as soon as possible after sched-Journal of The Korean Society of
Coloproctology
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uled chemotherapy has been completed.
The oncologic outcomes of oxaliplatin, in combination with 5- 
FU/LV, in this retrospective study were consistent with those in 
several trials, indicating that FOLFOX is effective and has an ac-
ceptable toxicity profile as an adjuvant chemotherapeutic agent in 
patients with stage III and high-risk stage II colon cancer who have 
undergone a potentially curative resection.
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